ArticleCancers2019

A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma.

Devalingam Mahalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.